DekaBank Deutsche Girozentrale Sells 184,131 Shares of Humana Inc. (NYSE:HUM)

DekaBank Deutsche Girozentrale cut its stake in Humana Inc. (NYSE:HUM) by 76.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,151 shares of the insurance provider’s stock after selling 184,131 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Humana were worth $19,848,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of HUM. Rakuten Securities Inc. bought a new position in shares of Humana in the fourth quarter worth about $25,000. Cetera Trust Company N.A acquired a new stake in shares of Humana during the 4th quarter worth approximately $28,000. Private Wealth Management Group LLC acquired a new stake in shares of Humana during the 4th quarter worth approximately $32,000. Carolinas Wealth Consulting LLC grew its position in shares of Humana by 274.1% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after buying an additional 74 shares during the period. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Humana during the 4th quarter worth approximately $55,000. 92.38% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HUM. Cantor Fitzgerald reiterated a “neutral” rating and set a $360.00 price target on shares of Humana in a research report on Tuesday, July 23rd. Piper Sandler started coverage on shares of Humana in a report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price objective for the company. Baird R W upgraded shares of Humana to a “hold” rating in a report on Thursday, May 30th. Royal Bank of Canada decreased their price objective on shares of Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Finally, Wells Fargo & Company decreased their price objective on shares of Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a report on Monday, April 8th. Fourteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $403.55.

Humana Stock Up 1.3 %

Shares of HUM stock traded up $4.64 during trading on Friday, reaching $363.62. The company’s stock had a trading volume of 1,076,306 shares, compared to its average volume of 1,396,067. The company has a quick ratio of 1.67, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The business has a fifty day moving average price of $367.90 and a 200-day moving average price of $347.51. Humana Inc. has a one year low of $298.61 and a one year high of $530.54. The company has a market cap of $43.78 billion, a price-to-earnings ratio of 22.64, a price-to-earnings-growth ratio of 2.09 and a beta of 0.51.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same period in the prior year, the firm posted $8.94 earnings per share. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Analysts anticipate that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.